Clincosm LogoSign in Get a demo

Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.

Sponsor
Taipei City Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05236309
Collaborator
(none)
2,000
Enrollment
1
Location
22.6
Actual Duration (Months)
88.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Taking a regional hospital as an example, the investigators will discuss the changes in the community cumulative incidence rate(CIR) and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak.

Main purpose:

Retrospective case study to explore the effect of traditional Chinese medicine on the prevention of SARS-CoV-2.

Secondary purpose:

If there are related side effects after taking Chinese medicine.

Condition or Disease Intervention/Treatment Phase
  • Drug: Jing-Guan-Fang(JGF) : Chinese herbal decoction

Detailed Description

The large-scale coronavirus epidemic is a major global public health challenge in the 21st century. Since the 2003 Severe acute respiratory syndrome (SARS) epidemic spread globally and caused hundreds of deaths, the Middle East respiratory syndrome (Middle East respiratory syndrome, MERS) and coronavirus disease 2019(COVID-19) has caused a large-scale global spread and also caused a huge impact on the public health and medical system. In the country's current epidemic (Aug 1, 2021), more than 15,000 people have been diagnosed, and the number of deaths has exceeded 800. Among them, the Taipei epidemic is the most severe, and the Wanhua District of Taipei City is the hot zone. The investigators will discuss the changes in accumulation incidence rate(CIR) of the community and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak.

This is a retrospective case study to explore the effect of traditional Chinese medicine on the prevention of SARS-CoV-2 and discuss if there are related side effects after taking Chinese medicine.

Study Design

Study Type:
Observational
Actual Enrollment :
2000 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
Taipei City Hospital Linsen Chinese Medicine and Kunming Branch
Actual Study Start Date :
Jan 1, 2020
Actual Primary Completion Date :
Jul 31, 2021
Actual Study Completion Date :
Nov 18, 2021

Arms and Interventions

Arm Intervention/Treatment
JGF (Jing-Guan-Fang): Traditional Chinese Medicine Decoction

JGF group: 100ml JGF decoction per day at least 1 week

Drug: Jing-Guan-Fang(JGF) : Chinese herbal decoction
Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.
Other Names:
  • Chinese herbal decoction

    		•
    NO JGF

    NO JGF group: None use traditional Chinese medicine(JGF)

    Outcome Measures

    Primary Outcome Measures

    1. Investigation on the effect of using traditional Chinese medicine to prevent SARS-CoV-2 infection in two groups with cumulative incidence rate(CIR). [18 months]

      Compare the dangerous states within two groups with CIR.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • From January 1, 2020 to July 31, 2021, Chinese medicine is used for patients with new coronary pneumonia epidemic prevention.
    Exclusion Criteria:

    1. Patients who do not use traditional Chinese medicine for the prevention of new coronary pneumonia.

    2. Patients who have signed and refused to provide medical records.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Taipei City Hospital Taipei Taiwan 886

    Sponsors and Collaborators

    • Taipei City Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Chung-Hua Hsu, Clinical Professor, Taipei City Hospital
    ClinicalTrials.gov Identifier:
    NCT05236309
    Other Study ID Numbers:
    • TCHIRB-11009019-E
    First Posted:
    Feb 11, 2022
    Last Update Posted:
    Mar 2, 2022
    Last Verified:
    Feb 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Chung-Hua Hsu, Clinical Professor, Taipei City Hospital
    Chinese medicine
    Additional relevant MeSH terms:
    COVID-19

    Study Results

    No Results Posted as of Mar 2, 2022